<SEC-DOCUMENT>0001104659-20-091457.txt : 20200806
<SEC-HEADER>0001104659-20-091457.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806162034
ACCESSION NUMBER:		0001104659-20-091457
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		201081999

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2020466-3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): </B>August 6, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SYNTHETIC
BIOLOGICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 36%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which <BR>
registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 &ndash; Results of Operations
and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2020,
Synthetic Biologics, Inc., a Nevada corporation (the &ldquo;Registrant&rdquo;) issued a press release that included financial information
for its quarter ended June 30, 2020. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information
contained in the press release is being furnished to the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and
shall not be deemed incorporated by reference into any of the Registrant&rsquo;s registration statements or other filings with
the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="tm2020466d3_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1 Press Release issued by Synthetic Biologics, Inc., dated August 6, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 6, 2020</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">and Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><A HREF="tm2020466d3_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="tm2020466d3_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Synthetic Biologics, Inc., dated August 6, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>tm2020466d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="tm2020466_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports 2020 Second
Quarter Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>-- <I>Announced FDA Clearance of IND
Application for SYN-020 Intestinal Alkaline Phosphatase (IAP) -- </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Signed Option License Agreement
with Massachusetts General Hospital to Develop SYN-020 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>to Treat and Prevent Metabolic and
Inflammatory Diseases Associated with Aging -- </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Enrollment in the Phase 2b Investigator-Sponsored
Clinical Trial of SYN-010 Has Recommenced </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Following COVID-19-Related Postponement
--</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today at 4:30 p.m.
(ET) --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, August 6, 2020 &ndash;</B></FONT> <U>Synthetic Biologics, Inc</U>. <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT>
a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today provided a clinical programs update and reported
financial results for the quarter ended June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the second quarter, we remained
diligently focused on advancing our portfolio of GI and microbiome-focused clinical development programs while continuing to navigate
the unprecedented global health and economic crisis sparked by the COVID-19 global pandemic,&rdquo; said Steven A. Shallcross,
Chief Executive and Financial Officer of Synthetic Biologics. &ldquo;We made significant progress positioning SYN-020, our orally
delivered recombinant version of bovine intestinal alkaline phosphatase (IAP), for its first clinical trial. We were pleased to
report the FDA responded to our Investigational New Drug application (IND) with a study-may-proceed letter to conduct a Phase
1 single ascending dose study of SYN-020 in healthy volunteers. Additionally, we expanded our collaboration with Massachusetts
General Hospital (MGH) in the form of an exclusive option agreement to license intellectual property and technology to commercially
develop SYN-020 for the treatment and prevention of metabolic and inflammatory diseases associated with aging. The Phase 1 clinical
trial is intended to support the clinical development of SYN-020 in multiple indications, including an initial indication for
the treatment of radiation enteropathy secondary to pelvic cancer therapy and indications that may be developed under the MGH
license agreement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross continued, &ldquo;Enrollment in the Phase 2b
investigator-sponsored clinical trial of SYN-010, intended to treat irritable bowel syndrome-constipation (IBS-C) and being conducted
out of Cedars-Sinai Medical Center (CSMC), has recommenced following a temporary postponement during the first and second quarter
due to the impact of the COVID-19 global pandemic. A data readout in the form of an interim futility analysis is expected during
the third quarter and topline data is anticipated during the first quarter of 2021, subject to potential COVID-19 complications.&rdquo;
Mr. Shallcross concluded, &ldquo;We remain in close contact with Washington University as we continue to evaluate opportunities
to initiate the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients
in the face of the ongoing COVID-19 pandemic. We continue to closely monitor the crisis caused by the spread of the COVID-19 and
look forward to sharing important updates and progress for this and all our GI and microbiome-focused clinical programs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Development and Operational
Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD> Submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for SYN-020, the
    Company&rsquo;s recombinant version of bovine intestinal alkaline phosphatase (IAP) supporting an initial indication to
    mitigate the intestinal damage caused by radiation therapy routinely used to treat pelvic cancers (Q2 2020)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Received study-may-proceed letter from FDA to conduct a Phase 1 single ascending dose study in
healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters (Q3 2020),</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 1 clinical program is intended to support the clinical development of SYN-020 in multiple
indications, including an initial indication for the treatment and prevention of radiation enteropathy secondary to cancer therapy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Entered into an agreement with Massachusetts General Hospital (MGH) granting the Company an option
for an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health,
diminish systemic inflammation, and treat age-related diseases (Q2 2020)</TD></TR>                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Under the terms of the agreement, Synthetic Biologics is granted exclusive rights to negotiate
a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated
with aging,</TD></TR>                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">If executed, the Company plans to use this license in the advancement of an expanded clinical development
program for SYN-020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Enrollment in the investigator-sponsored Phase 2b clinical trial of SYN-010, intended to treat
IBS-C, has recommenced following a temporary halt in Q1 and Q2 2020 due to the COVID-19 global pandemic; however, the ability to
continue to recruit new patients into this clinical trial remains at the discretion of CSMC and contingent upon the impact of the
COVID-19 global pandemic</TD></TR>                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A data readout in the form of an interim futility analysis is expected during the third
                                                                                                                             quarter of 2020 and topline data is anticipated during the first quarter of 2021, subject to the impact of COVID-19,</TD></TR>                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">CSMC and Synthetic Biologics are co-funding the study. The patent rights covering the use of SYN-010
are owned by CSMC and are exclusively licensed by CSMC to Synthetic Biologics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Received written notification from the FDA informing the Company that the FDA determined the Phase
1b/2a clinical program in adult allogeneic hematopoietic cell transplant (HCT) recipients may proceed per the submitted clinical
program protocol (Q3 2020)</TD></TR>                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Due to the unique challenges posed by the global COVID-19 pandemic, Washington University continues
to evaluate non-essential activities, which may have a direct impact on planned and ongoing clinical trials, including the SYN-004
(ribaxamase) Phase 1b/2a clinical program in allogeneic HCT recipients,</TD></TR>                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">At this time, the Company has determined that postponing the initiation of the planned Phase 1b/2a
clinical trial in allogeneic HCT recipients until at least the first quarter of 2021 remains the appropriate course of action due
to continued uncertainty surrounding the ongoing global COVID-19 pandemic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On
                                         July 30, 2020, the Company received written communication from NYSE American LLC (the
                                         &ldquo;Exchange&rdquo;), the Company&rsquo;s current listing exchange, stating that in
                                         addition to Section 1003(iii), it is now also not in compliance with both Section 1003(i)
                                         and Section 1003(ii) of the NYSE American Company Guide since it reported a stockholders&rsquo;
                                         deficit of ($4.0) million as of March 31, 2020 and losses from continuing operations
                                         and/or net losses in its five most recent fiscal years ended December 31, 2019</TD></TR>                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The
                                         Company has previously submitted a plan of compliance which was accepted by the Exchange
                                         addressing how it intends to regain compliance with the Exchange continued listing standards
                                         by November 25, 2020, the end of the current compliance plan period,</TD></TR>                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13.5pt">&nbsp;</TD>
    <TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The NYSE American notification does not affect the Company&rsquo;s
    business operations or the listing of the Company&rsquo;s shares on the Exchange, and does not represent any change or amendment
    to the Company's consolidated financial statements or to its quarterly reports for the quarter ended March 30, 2020 or to
    its annual report on Form 10-K for the year ended December 31, 2019.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Quarter Ended June 30, 2020 Financial
Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
by 23% to $1.3 million for the three months ended June 30, 2020, from $1.0 million for the three months ended June 30, 2019. This
increase is primarily due to increased legal costs related to business development, patent execution and employee contract matters,
vacation expense, and insurance costs. The charge related to stock-based compensation expense was $67,000 for the three months
ended June 30, 2020, compared to $59,000 the three months ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased
by 38% to $1.6 million for the three months ended June 30, 2020, from $2.6 million for the three months ended June 30, 2019. This
decrease is primarily the result of the response to the global COVID-19 pandemic by our clinical development partners which led
to the postponement of the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients and a temporary halt
during the second quarter in new enrollment in the Phase 2b investigator sponsored clinical trial of SYN-010. The charge related
to stock-based compensation expense was $19,000 for the three months ended June 30, 2020, compared to $31,000 for the three months
ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $6,000 for the three months
ended June 30, 2020, compared to other income of $80,000 for the three months ended June 30, 2019. Other income for the three months
ended June 30, 2020 and 2019 is primarily comprised of interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents as of June 30,
2020 totaled $8.1 million, a decrease of $7.0 million from December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics will hold a conference call today, Thursday,
August 6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">, 2020, at 4:30 p.m. (EST).</FONT> The dial-in
information for the call is as follows, U.S. toll free: 1-888-347-5280 or International: +1 412-902-4280. Participants are asked
to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at <U>https://www.webcaster4.com/Webcast/Page/1096/35797</U>.
An archive of the call will be available for replay at the same URL, <U>https://www.webcaster4.com/Webcast/Page/1096/35797</U>,
for 90 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company's lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed
to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome
damage, <I>C. difficile</I> infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR)
and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which
is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable
bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics'
website at <U>www.syntheticbiologics.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and include statements regarding the Phase 1 clinical trial of SYN-020 supporting the clinical development of SYN-020 in multiple
indications, a data readout in the investigator-sponsored Phase 2b clinical trial of SYN-010 in the form of an interim futility
analysis during the third quarter and topline data during the first quarter of 2021, subject to potential COVID-19 complications,
and use of the license with MGH in the advancement of an expanded clinical development program for SYN-020. These forward-looking
statements are based on management&rsquo;s expectations and assumptions as of the date of this press release and are subject to
a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially
from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors
that could cause actual results to differ materially from current expectations include, among others, a failure to receive the
necessary regulatory approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo;
clinical trials, and those conducted by investigators, for SYN-004, SYN-010 and SYN-020 to be commenced or completed on time or
to achieve desired results and benefits, especially in light of COVID-19, a failure of Synthetic Biologics&rsquo; clinical trials
to continue enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market
or sell its products, Synthetic Biologics&rsquo; inability to maintain its material licensing agreements, a failure to maintain
our listing on the NYSE American, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize
products and other factors described in Synthetic Biologics&rsquo; Annual Report on Form 10-K for the year ended December 31,
2019 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this
release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking
statements contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>(in thousands, except share and per share amounts)</I></B></FONT> &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2019</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,059</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">15,045</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">897</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,381</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">251</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">367</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Right of Use Asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">352</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,582</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,235</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholder&rsquo;s Deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,763</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,748</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Series A Convertible Preferred Stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,669</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,544</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.1in">Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,966</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,821</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.1in">Non-controlling interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,884</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,878</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,582</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,235</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Consolidated Statements of Operations</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif">(In thousands except share and per share amounts)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended<BR> June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the six months ended<BR> June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,286</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,044</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,679</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,199</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,603</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,594</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,238</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,012</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,889</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,638</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,917</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,211</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,889</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,638</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,917</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,211</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">125</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net
Loss </B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,883</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,558</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,873</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,086</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(42</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(43</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,867</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,531</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,831</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,043</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;Series A Preferred Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(61</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(125</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;&nbsp;Series B Preferred Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(392</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(117</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(796</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(515</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,322</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,709</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,752</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,680</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share &ndash; Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.38</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.48</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Weighted average number of common shares outstanding - Basic and Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,405,884</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,465,314</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,748,688</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,063,283</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">#&nbsp; #&nbsp;&nbsp; #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2020466_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2020466_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !9 24# 2(  A$! Q$!_\0
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M'A<QH8>C6C3C2Q5/)J.34,1BJCY)0^LRS#.<5B*4)1E*I",9PE&,(J/S7]K
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M )&P"&49++Q7]M7[#]NR_L6?LA*2S"/]E[X %0?D4%/A3X0;.Q BL3)'YA+
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M?SMH/T']MC_@OO\ '7P5K'[37@+QA^T7KWPFT!/%&IMXH\%?##P1I'@FWM-
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M9Z)JLIQ:_DI^P/\ \' 7C#]B'X-:#^RU^T%^SCJ?C>'X//=>%O"6IZ)KFJ^
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MXJ_LD>'?#FHR^&+74-$\<^(_AOXGM%\4:M=+K<V[PE9Q3P7$DD-D+F3S0CF
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M[O;M!VX_IO\ V/0\_P"RM\%/M$DP\[X?:8$=BI(L$BEBL"I*<!=.2&--P8%
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MN<"(G8V2WS';EA\I.%&VJ+2/S&8%E.&W!(TB5MV0=X4!&.#]]E+' Y(JU/\
M\?47^X/YR5:/3_@"_P Q3J59T8TW%W<_=3:7N)MK335>5T.=*5Z4G44[KFBJ
MM'#U715[6H3G2<Z:TOHV[MZ[6RT@A0[BSX+"+;O20$MM + H4'RJ5"JH7YF(
M7<0PD6.!9$V#;R\@"@88J '9MN &(7G "_+T]7-U3_KK%_-ZIK]^+_KE<_\
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#*/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
